TWST 42.00 Stock Price Twist Bioscience Corporation
Range: | 23.07-60.9 | Vol Avg: | 755851 | Last Div: | 0 | Changes: | 0.57 |
Beta: | 1.78 | Cap: | 2.51B | Currency: | USD | Exchange: | NASDAQ |
Sector: | Healthcare | IPO: | Wed Oct 31 2018 | Empoloyees: | 919 |
CUSIP: | 90184D100 | CIK: | 0001581280 | ISIN: | US90184D1000 | Country: | US |
CEO: | Dr. Emily Marine Leproust Ph.D. | Website: | https://www.twistbioscience.com |
Twist Bioscience Corporation, a synthetic biology company, manufactures and sells synthetic DNA-based products. The company's DNA synthesis platform enables the manufacturing of synthetic DNA by writing DNA on a silicon chip. It offers synthetic DNA-based products, including synthetic genes, tools for sample preparation, antibody libraries for drug discovery and development, and DNA as a digital data storage medium. The company has collaboration agreements with Victorian Clinical Genetic Services; Vivlion GmbH.; Kyowa Kirin Pharmaceutical Research, Inc.; deepCDR Biologics AG; and Centogene N.V to develop advanced sequencing tools. It also has a research collaboration with Boehringer Ingelheim International GmbH to use proprietary antibody libraries to discover therapeutic antibodies against multiple targets. Twist Bioscience Corporation was incorporated in 2013 and is headquartered in South San Francisco, California.
The content provided on this site is for informational purposes only and does not constitute financial, investment, or professional advice. We are not registered investment advisors or financial planners, and we do not provide recommendations or advice on buying, selling, or holding any particular stocks or securities. Any investment decisions should be made based on your own research and consultation with a qualified financial professional. We are not responsible for any financial loss or damages incurred from reliance on the information provided on this site. Please invest responsibly and seek professional advice when needed.